ClinicalTrials.gg
CompletedNCT07103369Updated Aug 8, 2025

A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

A Phase 1 interventional study of SM17 for injection and SM17 placebo for injection in Atopic Dermatitis, sponsored by SinoMab BioScience Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by SinoMab BioScience Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry.
  • Registered 1 year 8 months after the study started (first participant enrolled Nov 2023, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
150th of 190
64 · median 164
Started
2023
with 38 others
Phase 1
38 of 206
14 open now
Registered
156th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 150th largest by enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 38 in phase 1, and was the 156th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This trial is a phase 1, randomized, double-blind, placebo-controlled trial conducted in Chinese Healthy Volunteers and Patients with moderate-to-severe Atopic Dermatitis

It aims to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of single and multiple doses of SM17 injection in healthy subjects . It also aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect and immunogenicity as well as preliminary efficacy in AD patients.

Read the detailed description

This trial consists of 2 parts:

Part 1 (Ph1a) trial of the study is a dose-ascending study to evaluate the safety, tolerability, pharmacokinetic characteristics of SM17 in Chinese healthy volunteers. Safety and PK profiles of SM17 in Chinese population will be established firstly in this study following single and multiple doses of SM17 injection, and possible differences to those of SM17 in US populations will also be evaluated.

Part2 (ph1b) trial of the study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of SM17 in treating patients with moderate-to-severe atopic dermatitis(AD) following multiple doses of SM17 injections at two doses level of SM17 or placebo. PK/PD profiles, immunogenicity profile of SM17 in AD patients will also be evaluated.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Volunteers:

  • Male or Female,19\~55 years old
  • ≥18.5 and \<28.0 kg/m² at the screening visit, with body weight ≥50 kg for males and ≥45 kg for females
  • Non-smokers or former smokers who have quit for at least 6 months, with a smoking history of \<10 pack-years for former smokers at the screening visit. No history of alcohol consumption or light alcohol consumption prior to the screening visit.
  • No abnormalities or abnormalities of no clinical significance (NCS) in vital signs, physical examination, laboratory tests, or (ECG) results during the screening period, \<450 msec for male and QTcF \<470 msec for female subjects.
  • Use one medically approved method during the trial and for 6 months after the trial ends (specific methods see Appendix 1); No plans to donate sperm/ova during the trial and for 6 months after the trial ends.
  • .

Eligible patients must have a history of inadequate response or intolerance to treatment with topical AD medications.

  • Male or female, 18 \~70 years old
  • Atopic dermatitis (Hanifin \& Rajka) at the screening visit with eczema symptoms reported over 1year
  • Eczema Area and Severity Index (EASI) score ≥16 at the screening and baseline visits
  • Investigator's Global Assessment (IGA) score ≥3 at the screening and baseline visits
  • ≥10% body surface area (BSA) of AD involvement at the screening and baseline visits
  • Baseline pruritus numerical rating scale (NRS) weekly average score ≥4
  • Documented recent history (within 6 months before the screening visit) of inadequate response to topical AD medication(s) or for whom topical treatments are medically inadvisable (e.g. intolerance, because of important side effects, or safety risks)
  • Have applied a stable dose of topical bland emollient (moisturizer) at least twice daily for at least 7 consecutive days immediately before randomization
  • Willing and able to comply with all clinic visits and study-related procedures
  • Able to understand and complete study-related questionnaires
  • Signed written informed consent

Exclusion criteria

Exclusion Criteria:

Healthy volunteers:

  • Presence of psychiatric or legal incapacity, significant emotional problems at the screening visit, or anticipation of such issues during the study period.
  • Regular alcohol consumption within 6 months prior to screening.
  • History or evidence of any medical condition, situation, or disease.
  • Any laboratory parameter meeting the following criteria:

    1. Total (TBIL) >1.5 × (ULN)
    2. (ALT) or aspartate aminotransferase (AST) >2 × ULN
    3. Serum creatinine (Cr) >1.5 × ULN
    4. White blood cell count below the lower limit of normal (LLN), deemed clinically significant and unsuitable for inclusion by the investigator at screening or baseline.
  • History or current diagnosis of cardiovascular/cerebrovascular disease.
  • Prior hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
  • Evidence of any active or suspected bacterial, viral, fungal, or parasitic infection within 4 weeks prior to screening. Subjects deemed at high risk for parasitic diseases are also excluded.
  • Known diagnosis of Type I/II diabetes mellitus or prediabetes.
  • Administration of live (attenuated) vaccines within 1 month prior to first dose.
  • History of any within 5 years prior to screening (except successfully treated carcinoma in situ of the cervix or surgically excised non-melanoma skin cancer).
  • Any known history of primary or secondary immunodeficiency disorders.
  • Positive drug urine screen or alcohol consumption within 48 hours prior to screening.
  • History or presence of or idiosyncratic reactions to protein therapies, drugs, any component of SM17, or related compounds.
  • Active infection including: Tuberculosis (TB), , , .
  • Use of any prescription or non-prescription medication within 14 days or 5 half-lives (whichever longer) prior to first SM17 dose.
  • Tattoos, scars at/near the infusion site, or any other condition potentially interfering with infusion site examination, per investigator assessment.
  • Blood/plasma donation (≥500 mL) or significant blood loss within 2 months prior to screening; planned donation during study. Bone marrow donation within 3 months prior to first dose.
  • Inability to undergo protocol-required visits/procedures per investigator/subject knowledge.
  • Current/recent participation in another drug/device study.

AD patients:

  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study
  • Laboratory abnormality for serum hemoglobulin, WBC, neutrophils, , ALT/AST, TBIL, serum creatinine at screening or baseline
  • HIV/HBV/HCV/TB positive
  • abnormality with clinical significance
  • History of concomitant diseases: VKC/AKC, other skin diseases, active chronic or acute infection requiring treatment with systemic medications, malignancy within 5 yrs, other major diseases
  • History of acute allergies, or known allergies to composition of monoclonal antibodies or
  • Treatments within 4 weeks before the baseline visit, or is likely to require such treatment(s) during the study treatment:
  • systemic , Janus kinase inhibitors
  • other /immunomodulating drugs (cyclosporine, mycophenolate-mofetil, IFN-γ,, azathioprine, MTX..)
  • traditional Chinese medicine
  • Treatment with TCS, TCI, PDE-4 inhibitor, or other topical AD medications within 1 week before baseline
  • New treatment of anti-histamine or ICS within 1 week before baseline ( stable doses of anti-histamine or ICS is allowed during study)
  • Treatment with biologics, within 5 half-lives (if known) or 16 weeks prior to baseline visit, whichever is longer
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    SAD cohort 1

    single ascending dose cohort 1, participants(HVs) will receive 70mg of SM17 or placebo intravenously in this cohort with randomization ratio 6:2

    Drug: SM17 for injection · Other: SM17 placebo for injection

  • Experimental
    SAD cohort 2

    single ascending dose cohort 2, participants(HVs) will receive 200mg of SM17 or placebo intravenously in this cohort with randomization ratio 6:2

    Drug: SM17 for injection · Other: SM17 placebo for injection

  • Experimental
    SAD cohort 3

    single ascending dose cohort 3, participants(HVs) will receive 600mg of SM17 or placebo intravenously in this cohort with randomization ratio 6:2

    Drug: SM17 for injection · Other: SM17 placebo for injection

  • Experimental
    MD cohort

    multiple doses cohort, participants(HVs) will receive consecutive doses of 600mg of SM17 or placebo intravenously, once every 2 weeks in this cohort with randomization ratio 6:2

    Drug: SM17 for injection · Other: SM17 placebo for injection

  • Experimental
    SM17 lower dose group

    treatment group for participants (AD patients) to receive lower consecutive dose of SM17 (200mg)intravenously once every 2 weeks until end of treatment

    Drug: SM17 for injection

  • Experimental
    SM17 higher dose group

    treatment group for participants (AD patients) to receive higher consecutive dose of SM17 (200mg)intravenously once every 2 weeks until end of treatment

    Drug: SM17 for injection

  • Placebo comparator
    placebo group

    control group for participants (AD patients) to receive placebo doses intravenously once every 2 weeks until end of treatment

    Other: SM17 placebo for injection

Interventions

  • DrugSM17 for injection

    SM17 monoclonal antibody for intravenous infusion use

  • OtherSM17 placebo for injection

    placebo to be compared with SM17, excipient solution of SM17 monoclonal antibody without protein

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent AEs in each cohort(Ph1a)

    Safety and tolerability of SM17 in Chinese healthy volunteers administrated with SM17 or placebo intravenously. Treatment emergent AE was any unfavorable or unintended medical occurrence in each subject, including any abnormal changes in vital signs or lab testing with clinical significance judged by investigators, that happened during the period of receiving or after receiving the investigational product.

    Time frame: Day 0 to Day85 (SAD cohorts), Day 0 to Day 113 (MD cohort)

  2. Incidence of Treatment emergent AEs (TEAEs) in each treatment group(ph1b)

    Safety and tolerability of SM17 in Chinese AD patients administrated with SM17 or placebo intravenously. Treatment emergent AE was any unfavorable or unintended medical occurrence in each subject, including any abnormal changes in vital signs or lab testing with clinical significance judged by investigators, that happened during the period of receiving or after receiving the investigational product. changes in vital signs and lab testing

    Time frame: Week 0 to Week 16

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC) in Chinese healthy volunteers

    Serum Pharmacokinetic (PK) parameter of SM17 in Chinese healthy subjects administrated with SM17 intravenously

    Time frame: 12 weeks following SM17 dose (SAD) or last dose (MD)

  2. Immunogenicity

    ADA positive rate in Chinese healthy volunteers

    Time frame: Baseline to 12 weeks following SM17/placebo dose (SAD) or last dose(MD)

  3. Area under the plasma concentration versus time curve (AUC) in Chinese AD patients

    Pharmacokinetic parameter obtained from Chinese patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: Week 0 (baseline) to Week 16

  4. Efficacy for treating AD - EASI50%

    Portion of participants reaching response as EASI50(A 50% decrease in Eczema Area and Severity Index, which ranges from 0\~72, and a deeper decrease means better outcome) in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: Week12, Week 16

  5. Efficacy for treating AD-EASI75%

    Portion of participants reaching response as EASI75(A 75%50% decrease in Eczema Area and Severity Index, which ranged from 0\~72, and a deeper decrease means better outcome) in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: Week12, Week 16

  6. Efficacy for treating AD-EASI90%

    Portion of participants reaching response as EASI90(a 90% decrease in Eczema Area and Severity Index, which ranges from 0\~72, and a deeper decrease means better outcome) in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: Week12, Week 16

  7. Efficacy for treating AD-EASI score change

    EASI(Eczema Area and Severity Index) score(ranges 0\~72,higher score means worse disease condition) change from baseline and percentage change from baseline in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: Week2,4,6,8,10,12,16

  8. Efficacy for treating AD-IGA 0/1%

    Portion of participants reaching response as IGA 0/1 in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously. Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score ranges from 0 to 4, with lower scores indicating less severe AD. IGA 0/1 is defined as scores of 0 or 1, indicating a clear or almost clear AD presentation, and with at least 2-point reduction from baseline at time of assessment.

    Time frame: Week12, Week16

  9. Efficacy for treating AD- PP-NRS

    Change from baseline and Percentage change from baseline in PP-NRS weekly average score. PP-NRS is peak pruritus numeric rating scale, ranges 0\~10, with higher score indicating a more severe itch condition. PP-NRS is assessed by patients to evaluate the peak pruritus condition for the past 24 hrs. A weekly average score is calculated as mean value of PP-NRS scores of 7 consecutive days prior to the point of assessments (need at least scores from 4/7 days available required to get a valid weekly average score).

    Time frame: Baseline (Week0) to Week 16

  10. Efficacy for treating AD-NRS-4%

    Portion of participants reaching response as NRS-4 in Chinese patients with moderate-to-severe AD administrated with SM17 intravenously. PP-NRS is peak pruritus numeric rating scale, ranges 0\~10, with higher score indicating a more severe itch condition. NRS-4 is defined as at least 4 points reduction from baseline in weekly average score of PP-NRS. A weekly average score baseline is calculated as mean value of PP-NRS scores of 7 consecutive days prior to treatments (need at least scores from 4/7 days available to get a valid weekly average score baseline).

    Time frame: Week2,4,6,8,10,12,16

  11. Efficacy for treating AD-BSA%

    Change from baseline in Body Surface Area%(BSA%) with AD involvement, with a larger BSA% indicating a more severe disease condition.

    Time frame: Week 2,4,6,8,10,12,16

  12. Efficacy in treating AD-SCORAD

    Change from baseline and percentage change from baseline in SCORAD (SCORing Atopic Dermatitis), ranges 0\~103, with higher score indication a worse disease condition.

    Time frame: Week 4,8,10,12,16

  13. Efficacy for treating AD-POEM

    Change from baseline and Percentage change from baseline in POEM (Patient-Oriented Eczema Measure scores, range 0-28), with higher score indicating a worse disease condition.

    Time frame: Week2,4,6,8,10,12,16

  14. Efficacy for treating AD-DLQI

    Change from baseline in DLQI score (Dermatology Life Quality Index, range 0\~30, with higher score indicating a higher disease burden).

    Time frame: Week2,4,6,8,10,12,16

  15. Immunogenicity

    ADA positive rate in Chinese patients with moderate-to-severe AD treated by SM17/placebo intravenously

    Time frame: Week 0~16

Other outcomes

  1. PD biomarkers- total IgE

    Serum total IgE concentration (mg/L) tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo

    Time frame: Week0, 4, 8, 10, 12, 16

  2. Peak Plasma Concentration (Cmax) in healthy volunteers and AD patients

    PK parameter(Cmax) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b

  3. Time to peak (Tmax)

    PK parameter(Tmax) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b

  4. Elimination half-life (T1/2)

    PK parameter(T 1/2) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b

  5. Elimination Rate Constant (Kel)

    PK parameter(Kel) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b

  6. Total drug clearance from plasma (CL)

    PK parameter(CL) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b

  7. Apparent volume of distribution at steady state after extravascular administration (Vz)

    PK parameter(Vz) obtained from Chinese Healthy volunteers and patients with moderate-to-severe AD administrated with SM17 intravenously

    Time frame: 12 weeks following SM17 dose (SAD) or last dose( MD) for ph1a, 0~16 week for ph1b

  8. PD biomarker- Eosinophil counts

    Serum Eosinophil counts tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo

    Time frame: Week0,2,4,6, 8, 10, 12, 16

  9. PD biomarker- Tarc

    Serum Tarc (CCL17) concentration (pg/mL) tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo

    Time frame: Week0, 4, 8, 10, 12, 16

  10. PD biomarker-Eotaxin-3

    Serum Eotaxin-3 (CCL-26) concentration (pg/mL) tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo

    Time frame: Week0, 4, 8, 10, 12, 16

  11. PD biomarker- Periostin

    Serum Periostin concentration (ng/mL) tested from Chinese patients with moderate-to-severe AD, treated by SM17/placebo

    Time frame: Week0, 4, 8, 10, 12, 16

07

Study locations

1 site
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2025, 16 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 16 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 5, 2025
StartActual
Nov 21, 2023
Primary completionActual
Mar 24, 2025
CompletionActual
Mar 31, 2025
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07103369
Lead sponsor
SinoMab BioScience Ltd
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Nov 21, 2023
Primary completion
Mar 24, 2025
Completion
Mar 31, 2025
Last update
Aug 8, 2025

Study contacts

Xin-Hua Gao, MD
principal investigator · The First Hospital of China Medical University,Shenyang,Liaoning

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion